Bio-Path (BPTH) Q2 2024 earnings summary

Executive summary

• Achieved significant clinical and corporate milestones in the first half of 2024, advancing four oncology drug candidates through key development stages and presenting promising interim Phase II results for prexigebersen in AML at major oncology conferences.

• Advanced BP1002, BP1003, and BP1001-A clinical trials for hematologic and solid tumors, with BP1003 progressing toward IND submission.

• Developed a molecular biomarker package to enhance patient selection for prexigebersen therapy.

• The company reported a net loss for the quarter and continues to operate at a loss, with no significant revenue generated to date.

Financial highlights

• Net loss for Q2 2024 was $1.9 million ($1.16 per share), improved from $4.2 million ($10.64 per share) in Q2 2023; net loss for the six months ended June 30, 2024 was $5.0 million, down from $9.5 million for the same period in 2023.

• Research and development expenses decreased to $1.9 million from $3.1 million year-over-year, mainly due to lower manufacturing costs.

• General and administrative expenses remained steady at $1.2 million for both Q2 2024 and Q2 2023.

• Cash balance as of June 30, 2024 was $4.0 million, up from $1.1 million at year-end 2023, primarily due to $7.2 million in net proceeds from equity financings.

• Net cash used in operations was $4.3 million for the first half of 2024, down from $6.9 million in the prior year period.

Outlook and guidance

• Anticipates further clinical data readouts for BP1001-A in solid tumors later in 2024 and plans to finalize IND application for BP1003 following successful safety testing.

• Ongoing focus on advancing DNAbilize platform and expanding clinical pipeline, with plans to pursue FDA expedited programs and potential expansion into Europe.

• Management does not believe current cash is sufficient to fund operations for the next 12 months and substantial doubt exists about the company's ability to continue as a going concern without additional capital.